Project Grant K08HL179459
Award Date 8/22/25
Completion Date 7/31/30
Dollars Obligated $156K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $715,161 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis), to conduct research on the epigenetic regulation of pulmonary smooth muscle cell remodeling in pulmonary hypertension. The research aims to elucidate the molecular mechanisms by which the sphingosine kinase 2 (SPHK2) enzyme contributes to vascular...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $514,484 Project Grant to The Johns Hopkins University under the Cardiovascular Diseases Research program (CFDA 93.837) on August 24, 2025. The grant supports research to investigate the role of the kynurenine pathway, a metabolic process, in the pathobiology of pulmonary arterial hypertension (PAH). The key objectives are to determine if the enzyme tryptophan 2,3 dioxygenase (TDO) and its metabolite kynurenine serve as endogenous...
- This Project Grant award, valued at $1,385,536.00, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to Rhode Island Hospital, a division of Lifespan Corporation. The award, with a period of performance from March 1, 2025 to December 31, 2028, will support research focused on understanding endothelial cell dysfunction and the role of anoikis resistance in the development and progression of pulmonary arterial...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $637,126 to the Trustees of Indiana University (Indianapolis) for a research project titled "Deciphering the Novel Regulatory Mechanisms of Neovascularization, Cardiomyocyte Survival, and Endothelial Cell-Cardiomyocyte Crosstalk in Myocardial Infarction". The project aims to elucidate the roles of novel endothelial cell- and...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $730,070 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arizona on September 1, 2025. The goal of this research project is to develop and test a novel class of nanoparticle delivery systems that can selectively target lung capillary endothelial cells in vivo to deliver therapeutic genes like FOXM1 and stimulate lung regeneration in animal models of bronchopulmonary dysplasia (BPD)...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $193,896 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The 3-year grant, with a start date of March 1, 2025, aims to identify clinically available metrics that can serve as surrogates for right ventricular-pulmonary artery (RV-PA) coupling, a key indicator of right ventricular adaptation in pulmonary arterial hypertension (PAH) patients. The research will evaluate the...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $792,498 to the Trustees of Indiana University, Indianapolis (IU Indianapolis) to conduct research on hematopoietic stem cells (HSCs) and their regulation under low oxygen tension (hypoxia). The primary goals are to: 1) understand how hypoxia activates the transcription factor TFE3 to facilitate HSC self-renewal, 2) determine...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $487,567 to Indiana University to conduct integrative genomic analysis and develop high-dimensional risk prediction models for congenital heart defects (CHDs). The research aims to identify genetic variants and biological pathways associated with CHDs, as well as build predictive models leveraging genetic, epigenetic,...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $143,819 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of New Mexico Health Sciences Center (UNM HSC) on February 3, 2025. The purpose of this grant is to study the role of mitochondrial acid-sensing ion channel 1 (ASIC1) in pulmonary hypertension, a condition characterized by increased constriction and remodeling of the pulmonary arteries. The research aims to define the mechanisms...
- The National Heart Lung and Blood Institute (NHLBI), through the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $759,658 project grant to The General Hospital Corporation (Massachusetts General Hospital) to develop and validate a mechanomicroscopy system for the transbronchial assessment of pulmonary artery pressure and arterial smooth muscle thickening in patients with pulmonary hypertension due to lung disease (Group 3). The project aims to provide a clinically viable...